Minar E, Schillinger M
Medical University of Vienna, Angiology Medical University, Vienna, Austria.
J Cardiovasc Surg (Torino). 2012 Aug;53(4):481-6.
The concept of using a balloon catheter to directly deliver an antiproliferative drug at the site of injury has become one of the most interesting technological developments in endovascular therapy. There have been important advances in knowledge concerning balloon-based drug delivery technologies during the last years, and different methods have been developed by different companies to coat the balloon with the antiproliferative agent. Currently there is a rapidly increasing clinical study program using drug coated balloons (DCB) in different locations and indications. There are four already finished randomized studies in patients with superficial femoral artery lesions investigating the efficacy of paclitaxel release by DCB, and all demonstrated significantly improved patency rates compared to balloon angioplasty with non coated balloons. DCB offer several advantages compared to drug eluting stents, since any stentless technology for improvement of longterm patency is preferable to overcome the drawbacks of stenting. This technology has demonstrated the capacity to have a significant impact on the practice of percutaneous cardiovascular interventions in the future.
使用球囊导管在损伤部位直接递送抗增殖药物的概念已成为血管内治疗中最引人关注的技术发展之一。在过去几年中，关于基于球囊的药物递送技术的知识有了重要进展，不同公司开发了不同方法用抗增殖剂包覆球囊。目前，在不同部位和适应症中使用药物涂层球囊（DCB）的临床研究项目正在迅速增加。有四项针对股浅动脉病变患者的随机研究已经完成，这些研究调查了DCB释放紫杉醇的疗效，并且所有研究都表明，与使用未涂层球囊的球囊血管成形术相比，DCB的通畅率显著提高。与药物洗脱支架相比，DCB具有若干优势，因为任何用于改善长期通畅性的无支架技术都更可取，以克服支架置入的缺点。这项技术已证明有能力在未来对经皮心血管介入治疗的实践产生重大影响。
